Aa
A
A
Close
Avatar universal
GS-4774: an HBV-Specific Therapeutic Vaccine
Safety, Tolerability, and Immunogenicity of GS-4774, an HBV-Specific Therapeutic Vaccine, in Healthy Volunteers - Data from AASLD Liver Meeting 2013

http://www.natap.org/2013/AASLD/AASLD_74.htm
Cancel
1 Answers
Page 1 of 1
Avatar universal
Hi, GS-4774 demonstrated a favorable safety and immunogenicity profile in a previous Phase 1 clinical trial in patients with chronic hepatitis B virus (HBV) infection. This vaccine is aimed at declining the serum HBV surface antigen (HBsAg) in chronically infected patients. Regards.

Comment
Cancel
Comment
Avatar universal
Comment
Comment
Submit Comment
Your Answer
Avatar universal
Answer
Know how to answer? Tap here to leave your answer...
Answer
Submit Answer
A
A
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
Top Hepatitis Answerers
Avatar m tn
Blank
stef2011
Italy
Avatar m tn
Blank
sorte
Poland
Avatar m tn
Blank
Aduiski
Other
Avatar m tn
Blank
StephenCastlecrag
Australia
Avatar m tn
Blank
Liverpatient
Avatar f tn
Blank
flyinsky
paris, France